[New approaches to therapy in glomerulonephritis patients].
Riabov. S I SI; Rakitianskaia. I A IA; Stavskaia. V V VV; Nikitina. N A NA
Key Findings
- In‑vitro drug sensitivity testing is advised before starting therapy for chronic glomerulonephritis.
- Immunomodulation with thymalin (or tactivin) plus 3‑5 plasmapheresis sessions may enhance drug sensitivity.
- Standard chemotherapy (prednisolone or cyclophosphamide) follows the immunomodulation phase and lasts 4‑8 weeks, with maintenance for 1‑2 years.
Practical Outcomes
- For most biohackers, this protocol offers little actionable value unless they have diagnosed glomerulonephritis. Thymalin’s role here is limited to a niche clinical setting, so it isn’t a broadly applicable longevity or performance supplement.
Summary
The study suggests that before treating chronic glomerulonephritis, doctors should test how a patient’s cells respond to drugs, and if they’re not sensitive, they recommend using the peptide thymalin (or tactivin) together with several plasmapheresis sessions to boost drug sensitivity before giving standard chemotherapy. This protocol is specific to kidney disease patients and isn’t directly useful for general health‑optimization or longevity goals.
Abstract
Before starting treatment of chronic glomerulonephritis it is desirable to determine the patient's drug sensitivity in vitro because in the absence of such sensitivity chemotherapy should be preceded by immunomodulation with tactivin or thymalin and 3-5 sessions of plasmapheresis to stimulate drug sensitivity. Further measures include prednisolone or cyclophosphamide intravenously for 3-5 days in a dose 300-500 followed by oral administration. Active treatment lasts for 4-8 weeks. After that the patients receive maintenance for 1-2 years.
Study Information
pubmed
1996